Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT ID: NCT04052997

Last Updated: 2024-03-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 117 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-13
• Study Completion Date: 2023-01-19

Brief Summary

The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).

Detailed Description

This is a phase 2, multi-center, open-label, single-arm study of efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin lymphoma. This study will enroll approximately 100 participants.

Camidanlumab Tesirine (ADCT-301) is an antibody drug conjugate (ADC), composed of the human monoclonal antibody, HuMax®-TAC, which is directed against human CD25. The antibody is conjugated through a protease cleavable linker to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin.

For each participant the study will include a screening period (of up to 28 days), a treatment period (cycles of 3 weeks), and a follow-up period (approximately every 12-week visits) for up to 3 years after treatment discontinuation.

Participants may continue treatment for up to 1 year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.

Additionally, patients benefiting clinically at 1 year may continue treatment after a case by case review with the Sponsor.

Conditions

Relapsed Hodgkin Lymphoma; Refractory Hodgkin Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Camidanlumab Tesirine

Camidanlumab Tesirine is administered as a 30- minute intravenous (IV) infusion on Day 1 of each cycle (every 3 weeks). Camidanlumab Tesirine will be administered at a dose of 45 μg/kg every 3 weeks for 2 cycles, then 30 μg/kg for subsequent cycles.

Group Type: EXPERIMENTAL

Camidanlumab Tesirine

Intervention Type: DRUG

Intravenous Infusion

Interventions

Camidanlumab Tesirine

Intravenous Infusion

Intervention Type: DRUG

Other Intervention Names

ADCT-301

Eligibility Criteria

Inclusion Criteria

1. Written informed consent must be obtained prior to any procedures.

2. Male or female participant aged 18 years or older. (16 years or older at US based sites)

3. Pathologic diagnosis of classical Hodgkin lymphoma (cHL).

4. Patients with relapsed or refractory cHL, who have received at least 3 prior lines of systemic therapy (or at least 2 prior lines in HSCT ineligible patients) including brentuximab vedotin and a checkpoint inhibitor approved for cHL (e.g., nivolumab or pembrolizumab). Note 1: Receipt of HSCT to be included in the number of prior therapies needed to meet eligibility.

5. Measurable disease as defined by the 2014 Lugano Classification.

6. Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block (or minimum 10 freshly cut unstained slides if block is not available).

Note 1: Any biopsy since initial diagnosis is acceptable, but if several samples are available, the most recent sample is preferred.

Note 2: If a sufficient amount of tissue is not available, a fresh biopsy may be taken, provided the procedure is not deemed high-risk and is clinically feasible, and provided it is approved locally.

7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

8. Adequate organ function as defined by Screening laboratory values within the following parameters:

1. Absolute neutrophil count (ANC) ≥ 1.0 × 103/μL (off growth factors at least 72 h).

2. Platelet count ≥ 75 × 103/μL without transfusion in the past 2 weeks.

3. ALT, AST, or GGT ≤ 2.5 × the upper limit of normal (ULN) if there is no liver involvement; ALT or AST ≤ 5 × ULN if there is liver involvement.

4. Total bilirubin ≤ 1.5 × ULN (participants with known Gilbert's syndrome may have a total bilirubin up to ≤ 3 × ULN with direct bilirubin ≤ 1.5 × ULN).

5. Blood creatinine ≤ 3.0 × ULN or calculated creatinine clearance ≥ 30 mL/min by the Cockcroft-Gault equation.

Note: A laboratory assessment may be repeated a maximum of two times during the Screening Period to confirm eligibility.

9. Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test within 7 days prior to start of study drug for women of childbearing potential.

10. Women of childbearing potential (WOCBP) must agree to use a highly effective method of contraception from the time of giving informed consent until at least 9.5 months after the last dose of Camidanlumab Tesirine. Men with female partners who are of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 6.5 months after the participants receives his last dose of Camidanlumab Tesirine.

Exclusion Criteria

1. Previous treatment with Camidanlumab Tesirine.

2. Participation in another investigational interventional study. Being in follow-up of another investigational study is allowed.

3. Known history of hypersensitivity to or positive serum human anti-drug antibody (ADA) to a CD25 antibody.

4. Allogenic or autologous transplant within 60 days prior to start of study drug.

5. Active graft-versus-host disease (GVHD), except for non-neurologic symptoms as a manifestation of mild (≤ Grade 1) chronic GVHD.

6. Post-transplantation lymphoproliferative disorders.

7. Active second primary malignancy other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's medical monitor and Investigator agree and document should not be exclusionary.

8. History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjögren's syndrome, autoimmune vasculitis [e.g., Wegener's granulomatosis]) (subjects with vitiligo, type 1 diabetes mellitus, residual hypothyroidism, hypophysitis due to autoimmune condition only requiring hormone replacement may be enrolled).

9. History of neuropathy considered of autoimmune origin (e.g., polyradiculopathy including Guillain-Barré syndrome and myasthenia gravis) or other central nervous system autoimmune disease (e.g., poliomyelitis, multiple sclerosis).

10. History of recent infection (within 4 weeks of Cycle 1, Day 1 [C1D1]) considered to be caused by one of the following pathogens: HSV1, HSV2, VZV, EBV, CMV, measles, Influenza A, Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni, or enterovirus D68, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Note: An influenza test and a pathogendirected SARS CoV-2 test (such as polymerase chain reaction) are mandatory and must be negative before initiating study treatment (tests to be performed 3 days or less prior to dosing on C1D1; an additional 2 days are allowed in the event of logistical issues for receiving the results on time).

11. Participants known to be or having been infected with human immunodeficiency (HIV) virus, hepatitis B virus (HBV), or hepatitis C virus (HCV), and require anti-viral therapy or prophylaxis. Note: Serology testing is mandatory for patients with unknown status.

12. History of Stevens-Johnson syndrome or toxic epidermal necrolysis.

13. Failure to recover ≤ Grade 1 (Common Terminology Criteria for Adverse Events version 4.0 [CTCAE v4.0]) from acute non-hematologic toxicity (except ≤ Grade 2 neuropathy or alopecia), due to previous therapy, prior to screening.

14. Hodgkin lymphoma (HL) with central nervous system involvement, including leptomeningeal disease.

15. Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath).

16. Breastfeeding or pregnant.

17. Significant medical comorbidities, including uncontrolled hypertension (blood pressure [BP] ≥ 160/100 mmHg repeatedly), unstable angina, congestive heart failure (greater than New York Heart Association class II), electrocardiographic evidence of acute ischemia, coronary angioplasty or myocardial infarction within 3 months prior to screening, severe uncontrolled atrial or ventricular cardiac arrhythmia, poorly controlled diabetes, or severe chronic pulmonary disease.

18. Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic therapy, within 14 days prior to start of study drug, except shorter if approved by the Sponsor.

19. Use of any other experimental medication within 30 days prior to start of study drug.

20. Any live vaccine within 4 weeks prior to start of study drug and planned live vaccine administration after starting study drug.

21. Congenital long QT (measure between Q wave and T wave in the electrocardiogram) syndrome, or a corrected QTc interval of ≥ 480 ms, at screening (unless secondary to pacemaker or bundle branch block).

22. Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgment, make the participants inappropriate for study participation or put the participant at risk.

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ADC Therapeutics S.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Mayo Clinic - Arizona

Scottsdale, Arizona, United States

City of Hope Comprehensive Cancer Center

Duarte, California, United States

UCSF Health - Hematology and Blood and Marrow Transplant Clinic

San Francisco, California, United States

Stanford University Medical Center

Stanford, California, United States

Baptist MD Anderson Cancer Center

Jacksonville, Florida, United States

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States

Northside Hospital - Atlanta

Atlanta, Georgia, United States

The University of Chicago Medicine

Chicago, Illinois, United States

Norton Cancer Institute - Saint Matthews

Louisville, Kentucky, United States

University of Minnesota

Minneapolis, Minnesota, United States

Mayo Clinic

Rochester, Minnesota, United States

Washington University School of Medicine in Saint Louis

St Louis, Missouri, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

Memorial Sloan-Kettering Cancer Center - New York

New York, New York, United States

Stony Brook University Cancer Center

Stony Brook, New York, United States

University Hospitals Seidman Cancer Center

Cleveland, Ohio, United States

Cleveland Clinic - Taussig Cancer Center

Cleveland, Ohio, United States

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Hollings Cancer Center

Charleston, South Carolina, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

The University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Froedtert Hospital

Milwaukee, Wisconsin, United States

Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan

Bruges, , Belgium

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Grand Hôpital de Charleroi - Notre Dame

Charleroi, , Belgium

Hôpital de Jolimont

La Louvière, , Belgium

Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne

Yvoir, , Belgium

British Columbia Cancer Agency

Vancouver, British Columbia, Canada

The Ottawa Hospital - General Campus

Ottawa, , Canada

Princess Margaret Cancer Centre

Toronto, , Canada

Fakultní Nemocnice Brno

Brno, , Czechia

Fakultní Nemocnice Královské Vinohrady

Prague, , Czechia

Vseobecna fakultni nemocnice v Praze

Prague, , Czechia

Hôpitaux Universitaires Henri Mondor

Créteil, , France

Hôpital François Mitterrand

Dijon, , France

Clinique Victor Hugo Le Mans

Le Mans, , France

Hôpital Saint-Eloi

Montpellier, , France

Hôpital Haut-Lévêque

Pessac, , France

Centre Hospitalier Lyon-Sud

Pierre-Bénite, , France

Hôpital Pontchaillou

Rennes, , France

Centre de Lutte Contre le Cancer - Centre Henri-Becquerel

Rouen, , France

Universitätsklinikum Halle

Halle, , Germany

Debreceni Egyetem Klinikai Központ

Debrecen, , Hungary

Pécsi Tudományegyetem

Pécs, , Hungary

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo - Alessandria

Alessandria, , Italy

Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-Malpighi

Bologna, , Italy

Istituto Clinico Humanitas

Milan, , Italy

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

Napoli, , Italy

Istituto Oncologico Veneto - IRCCS

Padua, , Italy

Szpital Wojewódzki w Opolu

Opole, , Poland

Dolnośląskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku

Wroclaw, , Poland

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Hospital Universitari Vall d'Hebrón

Barcelona, , Spain

Hospital Clínic de Barcelona

Barcelona, , Spain

Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)

Barcelona, , Spain

Hospital General Universitario Gregorio Marañón

Madrid, , Spain

Hospital Universitario Fundación Jiménez Díaz

Madrid, , Spain

Hospital Universitario 12 de Octubre

Madrid, , Spain

Hospital Universitario La Paz

Madrid, , Spain

Hospital Universitario HM Sanchinarro

Madrid, , Spain

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Hospital Universitario Quirónsalud Madrid

Pozuelo de Alarcón, , Spain

Complejo Asistencial Universitario de Salamanca - Hospital Clínico

Salamanca, , Spain

Hospital Clínico Universitario de Valencia

Valencia, , Spain

Hospital Universitari i Politècnic La Fe

Valencia, , Spain

NHS Greater Glasgow and Clyde

Glasgow, , United Kingdom

University College London Hospitals NHS Foundation Trust

London, , United Kingdom

The Royal Marsden NHS Foundation Trust

London, , United Kingdom

The Christie NHS Foundation Trust

Manchester, , United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, , United Kingdom

University Hospitals Plymouth NHS Trust

Plymouth, , United Kingdom

Countries

United States; Belgium; Canada; Czechia; France; Germany; Hungary; Italy; Poland; Spain; United Kingdom

References

Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks KJ, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas O, Feldman TA, Hess BT, Bastos-Oreiro M, Iyengar S, Szomor A, Townsend W, Andre M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner JU, Carlo-Stella C. Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study. Blood Adv. 2025 Aug 14:bloodadvances.2024015600. doi: 10.1182/bloodadvances.2024015600. Online ahead of print.

Reference Type: DERIVED

PMID: 40811783 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2018-002556-32

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ADCT-301-201

Identifier Type: -

Identifier Source: org_study_id